CSF3 and neutropenia: It should be noted that five patients with grade 3 to 4 neutropenia were poorly responsive to G-CSF; however, neutropenia could be attenuated by reducing the DXT dose, increasing the interval between doses and decreasing the number of chemotherapy cycles.